Results 221 to 230 of about 4,546,789 (273)

GeoCross: A Privacy-Preserving and Fine-Grained Authorization Scheme for Cross-Chain Geological Data Sharing. [PDF]

Sensors (Basel)
Lin L, Feng B, Jing P.
europepmc   +1 more source

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Compassionate Use Program in Italy. [PDF]

Hematol Oncol
Zinzani PL, Dell'Omo G, Fusco L, Peduto I, Galeone C, Cavallo F, Gritti G.   +6 more
europepmc   +1 more source

Correction: Fault feature extraction for centrifugal pump impellers via EMD and cyclic bispectral slicing. [PDF]

Sci Rep
Liang X, Chen H, Wang L, Li S, Wang Z, Shi Z, Sheng X.   +6 more
europepmc   +1 more source

Challenges of access to care for children with cancer living in the Gaza Strip/occupied Palestinian territory in 2022: a cross-sectional study. [PDF]

BMJ Glob Health
Massad S, Isbeih M, Abu Saman K, Goncalves MB, Mahmoud L, Pourghazian N, Troisi G, Salman Z, Jeha S, Barkley S, Peeperkorn R.   +10 more
europepmc   +1 more source

Retraction: "Three-dimensional digital design of orthopedic surgery for idiopathic scoliosis deformity: A case series". [PDF]

J Int Med Res
europepmc   +1 more source

RETRACTION: The PI3K/mTOR Dual Inhibitor NVP‐BEZ235 Stimulates Mutant p53 Degradation to Exert Anti‐Tumor Effects on Triple‐Negative Breast Cancer Cells

FEBS Open Bio, EarlyView.
RETRACTION: J. Cai, J. Xia, J. Zou, Q. Wang, Q. Ma, R. Sun, H. Liao, L. Xu, D. Wang, and X. Guo, “The PI3K/mTOR Dual Inhibitor NVP‐BEZ235 Stimulates Mutant p53 Degradation to Exert Anti‐Tumor Effects on Triple‐Negative Breast Cancer Cells,” FEBS Open Bio 10, no. 4 (2020): 535–545, https://doi.org/10.1002/2211‐5463.12806.
wiley   +1 more source

Correction to: Factors Affecting Home Injuries in Older Adults: An Analysis Using Binary Logistic Regression. [PDF]

Health Sci Rep
europepmc   +1 more source